Cargando…

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis

BACKGROUND: Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC) patients. Some patients experience primary resistance to immunotherapy. Currently, we lack a marker of resistance to immunotherapy. Myeloid-derived suppressive-like cells (MDSCs) can reduce tumor respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bronte, Giuseppe, Petracci, Elisabetta, De Matteis, Serena, Canale, Matteo, Zampiva, Ilaria, Priano, Ilaria, Cravero, Paola, Andrikou, Kalliopi, Burgio, Marco Angelo, Ulivi, Paola, Delmonte, Angelo, Crinò, Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043492/ https://www.ncbi.nlm.nih.gov/pubmed/35493483 http://dx.doi.org/10.3389/fimmu.2022.866561

Ejemplares similares

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
por: Ulivi, Paola, et al.
Publicado: (2022)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
por: Verlicchi, Alberto, et al.
Publicado: (2023)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
por: De Matteis, Serena, et al.
Publicado: (2019)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA
por: Pasini, Luigi, et al.
Publicado: (2021)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
por: Nicolini, Fabio, et al.
Publicado: (2020)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

How to discriminate non-small cell lung cancer (NSCLC) cases from an Italian administrative database? A retrospective, secondary data use study for evaluating a novel algorithm performance
por: Balzi, William, et al.
Publicado: (2021)

Immune Checkpoints as a Target for Colorectal Cancer Treatment
por: Passardi, Alessandro, et al.
Publicado: (2017)

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
por: Siggillino, Annamaria, et al.
Publicado: (2020)

KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population
por: Fancelli, Sara, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection
por: Monti, Manlio, et al.
Publicado: (2017)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

The Endless Saga of Monocyte Diversity
por: Canè, Stefania, et al.
Publicado: (2019)

CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells
por: Zamagni, Alice, et al.
Publicado: (2020)

The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Monocyte-Derived Suppressor Cells in Transplantation
por: Ochando, Jordi, et al.
Publicado: (2015)

Comparative Analysis of Free-Circulating and Vesicle-Associated Plasma microRNAs of Healthy Controls and Early-Stage Lung Cancer Patients
por: Pasini, Luigi, et al.
Publicado: (2022)

Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
por: Ulivi, Paola
Publicado: (2016)

Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy
por: Nicolini, Andrea, et al.
Publicado: (2022)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature
por: Demichelis, Chiara, et al.
Publicado: (2020)

Perceptions of COVID-19 Vaccines: Protective Shields or Threatening Risks? A Descriptive Exploratory Study among the Italian Population
por: Boragno, Paola, et al.
Publicado: (2023)

Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dq00jj8nmam352jifb2tcnbcun